Stakeholders Call For FDA Policy On Patient Engagement In Clinical Trials

By Beth Wang / October 13, 2017 at 5:01 PM
During the first meeting of FDA’s Patient Engagement Advisory Committee (PEAC) on Wednesday (Oct. 11), patients and patient advocates, industry, and FDA discussed a need to craft regulatory policy around patient engagement in clinical trials and provided solutions for increasing and possibly incentivizing patient participation and retention in studies. Researchers called on FDA to implement regulations around patient engagement that would possibly help companies move toward more patient-centered drug development. And throughout the meeting, which featured roundtable discussions moderated by...


Not a subscriber? Sign up for 30 days free access to exclusive, detailed reporting on drug pricing reforms, Medicaid policy, FDA news and much more.